RE
GNCA

RBC Europe’s Genocea Biosciences, Inc. GNCA Stock Holding History

RBC Europe’s Portfolio GNCA Stock Details GNCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-3,125
Closed -$12.3K – 1101
2019
Q2 		$12.3K Hold
3,125
– – ﹤0.01% 764
2019
Q1 		$14.8K Hold
3,125
– – ﹤0.01% 722
2018
Q4 		$7.17K Hold
3,125
– – ﹤0.01% 866
2018
Q3 		$19.5K Hold
3,125
– – ﹤0.01% 682
2018
Q2 		$21.4K Hold
3,125
– – ﹤0.01% 663
2018
Q1 		$26.3K Buy
+3,125
New +$26K ﹤0.01% 619

Other funds holding GNCA

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RBC Europe's GNCA Position: Q3 2019 in Review

RBC Europe sold out of Genocea Biosciences, Inc. (GNCA) in Q3 2019, closing a stake of 3,125 shares — an estimated $12.3K sold.

RBC Europe first reported a position in GNCA in Q1 2018 and held it in 6 quarters. The position peaked at $26.3K in Q1 2018. 37 funds tracked by Wall St. Rank hold GNCA as of Q3 2019.

  • RBC Europe reported no remaining Genocea Biosciences, Inc. position as of Q3 2019 after selling out during the quarter.
  • RBC Europe sold 3,125 Genocea Biosciences, Inc. shares in Q3 2019, an estimated $12.3K.
  • RBC Europe first reported a position in Genocea Biosciences, Inc. in Q1 2018 and held it in 6 quarters.
  • RBC Europe's Genocea Biosciences, Inc. position peaked at $26.3K in Q1 2018.
  • 37 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q3 2019.

Based on RBC Europe's 13F filing for Q3 2019, filed 9 Nov 2023.